

Commercial SB1742 September 2025

Drug/Class	Effective Date	Overview
KHINDIVI SOLN	9/1/2025	Adding to formulary with PA
YEZTUGO TAB	9/1/2025	Adding to formulary with PA
YEZTUGO INJ	9/1/2025	Adding to formulary with PA
YUTREPIA CAP	9/1/2025	Adding to formulary with PA
VYVGART HYTRULO INJ	9/1/2025	Adding to formulary with PA
ARBLI SUSP	9/1/2025	Adding to formulary with PA
LOPRESSOR SOLN	9/1/2025	Adding to formulary with PA
AVERI TAB	9/1/2025	Adding to formulary with PA
WELIREG TAB	9/1/2025	Criteria added for Pheochromocytoma and Paraganglioma (PPGL) & verified clinical appropriateness
vigabatrin powder pack	9/1/2025	Update to PA criteria (Removed “monotherapy” from IS criteria; updated guidelines/position statements)
vigadrone powder pack	9/1/2025	Update to PA criteria (Removed “monotherapy” from IS criteria; updated guidelines/position statements)
vigabatrin tab	9/1/2025	Update to PA criteria (Removed “monotherapy” from IS criteria; updated guidelines/position statements)
KISQALI TAB	9/1/2025	Updated early breast cancer criteria to more closely match NCCN and study population
VERZENIO TAB	9/1/2025	Corrected endocrine therapy examples for metastatic criteria; verified clinical appropriateness